



Divi's Laboratories Limited

Date. 4th August 2018

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

Stock Code: DIVISLAB

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI – 400 001

Stock Code: 532488

Dear Sir/ Madam,

Sub: Un-audited financial results for the first quarter ended 30th June 2018 and limited review report –reg

Ref: Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Further to our letter dated 23rd July, 2018, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 4th August 2018 has approved Un-audited Financial Results for the first quarter ended 30th June, 2018.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following:

1. Un-audited Standalone Financial Results for the first quarter ended 30th June 2018.
2. Limited Review Report on the Standalone Financial Results
3. Press Release on the Financial Results of the Company

The Board meeting commenced at 10:30 Hrs and concluded at 12:50 Hrs

This is for your information and records.

Thanking You,

Yours faithfully,

For Divi's Laboratories Limited


P V Lakshmi Rajani
Company Secretary



“An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company”

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : 91-40-2378 6300, Fax : 91-40-2378 6460, CIN : L24110TG1990PLC011854

E-mail : mail@divislaboratories.com, Website : www.divislaboratories.com

DIVI'S LABORATORIES LIMITED
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH JUNE, 2018

(₹ in Lakhs)

	Particulars	Quarter ended			Year ended
		30.06.2018	31.03.2018	30.06.2017	31.03.2018
		(Unaudited)	(Audited)*	(Unaudited)	(Audited)
1	Revenue from operations (Refer Notes 4 & 5)	99531	108795	82120	383723
2	Other Income	4879	4817	2968	11248
3	Total Revenue from Operations (1+2)	104410	113612	85088	394971
4	Expenses				
	a) Cost of materials consumed	39767	48071	32152	152428
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1623)	(7308)	1007	(1938)
	d) Employee benefits expense	12133	12577	10070	44627
	e) Depreciation and amortization expense	4160	3879	3231	14242
	f) Finance Costs	64	(17)	49	133
	g) Other Expenses	14068	16805	14409	63543
	Total expenses	68569	74007	60918	273035
5	Profit before exceptional Items and tax (3-4)	35841	39605	24170	121936
6	Exceptional items	-	-	-	-
7	Profit before Tax (5-6)	35841	39605	24170	121936
8	Tax Expense				
	a) Current Tax	8566	12261	4827	28713
	b) Deferred Tax	659	1184	1689	6265
	Total Tax Expense	9225	13445	6516	34978
9	Net Profit for the period (7-8)	26616	26160	17654	86958
10	Other Comprehensive Income:				
	a) Items that will not be reclassified to Profit or Loss	24	233	(46)	94
	b) Items that will be reclassified to Profit or Loss	-	-	-	-
	Current tax relating to OCI	(7)	(55)	10	(27)
	Total other comprehensive Income	17	178	(36)	67
11	Total comprehensive Income for the period (9+10)	26633	26338	17618	87025
12	Paid-up Equity Share Capital (Face Value: Rs.2 per share)	5309	5309	5309	5309
13	Other Equity				590656
14	Earnings per Share (of Rs.2/- each) (not annualized)				
	a) Basic	10.03	9.85	6.65	32.76
	b) Diluted	10.03	9.85	6.65	32.76



[Handwritten Signature]



NOTES:

1. The above results, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 4th August, 2018. Results for the quarter ended 30th June 2018 were subjected to 'limited review' by the Auditors and their report contains no qualification.
2. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS 108.
3. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
4. The Ministry of Corporate Affairs (MCA) on 28th March 2018 notified Ind AS 115 "Revenue from contracts with customers" as part of the Companies (Indian Accounting Standards) Amendment Rules, 2018. The new Standard is effective for reporting periods beginning on or after 01st April 2018. The adoption of the standard did not have any material impact to the financial results of the company.
5. Post implementation of Goods and Service Tax (GST) effective from 1st July, 2017, revenue is reported net of GST as per Ind AS-18. Revenue, however, is reported inclusive of excise duty for the previous periods. Had the previously reported revenue been shown net of excise duty, comparative revenue of the company would have been as under:

(₹ in Lakhs)

Particulars	Quarter ended			Year ended
	30.06.2018	31.03.2018	30.06.2017	31.03.2018
Revenue from operations (net of excise duty)	99531	108795	81263	381735

6. * Figures for the quarter ended 31.03.2018 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the financial year.
7. As per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
8. Details of forex gain are given below:

(₹ in Lakhs)

Particulars	Quarter ended			Year ended
	30.06.2018	31.03.2018	30.06.2017	31.03.2018
Forex gain	2669	2297	701	2460

9. Figures for the previous year/period have been regrouped wherever necessary.

Place: Hyderabad
Date: 4th August, 2018



for Divi's Laboratories Limited

[Signature]
Dr. Murali K. Divi
Chairman & Managing Director




Price Waterhouse Chartered Accountants LLP

The Board of Directors
Divi's Laboratories Limited
Divi Towers, 1-72/23(P)/DIVIS/303,
Cyber Hills, Gachibowli,
Hyderabad- 500 032

1. We have reviewed the unaudited financial results of Divi's Laboratories Limited (the "Company") for the quarter ended June 30, 2018 which are included in the accompanying Statement of Standalone Unaudited financial results for the quarter ended June 30, 2018 (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The financial results of the Company for the quarter ended June 30, 2017 was reviewed by another firm of chartered accountants who issued their unmodified conclusion, vide their report dated July 22, 2017. Our conclusion is not qualified in respect of these matters.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: FRN 012754N/N500016


Sunit Kumar Basu
Partner
Membership Number: 55000

Place: Hyderabad
Date: August 04, 2018

*Price Waterhouse Chartered Accountants LLP, Plot No. 77/A, 8-2-624/A/1, 3rd Floor, Road No. 10, Banjara Hills
Hyderabad - 500 034
T: +91 (40) 4424 6000, F: +91 (40) 4424 6300*

Registered office and Head office: Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi 110 002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

DIVI'S LABORATORIES LIMITED
CIN No.L24110TG1990PLC011854
1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli
Hyderabad – 500 032 Telangana, India
Phone: 23786300 email: kishore@divislabs.com

PRESS RELEASE dated 4th August, 2018

Divi's Labs earns a total income of Rs. 1044 crores for Q1 of FY19

Divi's Laboratories has earned a total income of Rs. 1044 crores for the 1st quarter of the year 2018-19 on a stand-alone basis, as against an income of Rs. 851 crores for the corresponding quarter of last year.

The company earned a Profit before Tax (PAT) of Rs. 358 crores, for the current quarter. PBT for the corresponding quarter of the last year was Rs. 242 crores.

The company earned a Profit after Tax (PAT) of Rs. 266 crores before Other Comprehensive Income, for the current quarter. PAT for the corresponding quarter of the last year was Rs. 177 crores.

Operations of the current quarter reflects normalized operations after successful closure of audits by US-FDA for company's manufacturing sites, Unit-1 and Unit-2.

Forex gain for the current quarter amounted to Rs. 27 crores as against a gain of Rs. 7 crore during the corresponding quarter of the last year.

The company's Unit-I at Choutuppal, Telangana State has been inspected by the US-FDA during May 2018. This was a general cGMP inspection by the FDA and the inspection was concluded without any observations.

